Get the Stockscreener App
493.99
1.12%
5.48
United Therapeutics Corp stock is traded at $493.99, with a volume of 491.59K.
It is up +1.12% in the last 24 hours and up +7.03% over the past month.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
See More
Previous Close:
$488.51
Open:
$491
24h Volume:
491.59K
Relative Volume:
0.84
Market Cap:
$21.27B
Revenue:
$3.08B
Net Income/Loss:
$1.24B
P/E Ratio:
19.29
EPS:
25.6108
Net Cash Flow:
$1.07B
1W Performance:
+0.96%
1M Performance:
+7.03%
6M Performance:
+72.64%
1Y Performance:
+36.61%
1-Day Range:
$488.75
$496.73
1-Week Range:
$474.59
$496.73
52-Week Range:
$266.98
$496.73
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.70B | -157.13M | 1.19B | -0.1446 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Underweight |
| Sep-26-25 | Initiated | RBC Capital Mkts | Outperform |
| Jun-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-21-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
AQR Capital Management LLC Boosts Stake in United Therapeutics Corporation $UTHR - MarketBeat
Insider Sell: Jan Malcolm Sells Shares of United Therapeutics Co - GuruFocus
United Therapeutics stock hits all-time high at 492.62 USD - Investing.com
Investment Management Corp of Ontario Has $1.57 Million Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
Insider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells 187 Shares of Stock - MarketBeat
Insider Sell: Nilda Mesa Sells Shares of United Therapeutics Cor - GuruFocus
United Therapeutics (NASDAQ:UTHR) CFO Sells $10,050,600.00 in Stock - MarketBeat
Why a $27 Million Buy Signals New Confidence in Weatherford Stock - The Motley Fool
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term - Yahoo Finance
Chmn Rothblatt Files To Sell 4,000 Of United Therapeutics Corp [UTHR] - TradingView
Rothblatt, United Therapeutics CEO, sells $3.8m in UTHR stock By Investing.com - Investing.com Canada
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 Shares - MarketBeat
Rothblatt, United Therapeutics CEO, sells $3.8m in UTHR stock - Investing.com
United Therapeutics Insider Sold Shares Worth $3,870,056, According to a Recent SEC Filing - marketscreener.com
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells 8,000 Shares - TradingView
Chmn Rothblatt Sells 8,000 ($3.9M) Of United Therapeutics Corp [UTHR] - TradingView
Invesco Ltd. Grows Position in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corporation $UTHR Shares Acquired by Marshall Wace LLP - MarketBeat
United Therapeutics Corporation $UTHR Position Cut by Schroder Investment Management Group - MarketBeat
Epoch Investment Partners Inc. Has $83.76 Million Holdings in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (UTHR): Revisiting Valuation After Q3 2025 Growth, Strong 2027 Guidance and Rising Institutional Interest - simplywall.st
UTHR SEC FilingsUnited Therapeutics Corp. 10-K, 10-Q, 8-K Forms - Stock Titan
Insider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells 22,500 Shares of Stock - MarketBeat
State Board of Administration of Florida Retirement System Has $12.22 Million Position in United Therapeutics Corporation $UTHR - MarketBeat
Russell Investments Group Ltd. Lowers Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Executives Sell Shares Under 10b5-1 Trading Plans - TradingView
Korea Investment CORP Sells 18,300 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Pres Benkowitz Files To Sell 112,500 Of United Therapeutics Corp [UTHR] - TradingView
United Therapeutics Corporation $UTHR Shares Acquired by Hsbc Holdings PLC - MarketBeat
Virtus Investment Advisers LLC Boosts Stake in United Therapeutics Corporation $UTHR - MarketBeat
XTX Topco Ltd Has $1.39 Million Holdings in United Therapeutics Corporation $UTHR - MarketBeat
1,280 Shares in United Therapeutics Corporation $UTHR Purchased by Inceptionr LLC - MarketBeat
Charles Schwab Investment Management Inc. Decreases Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Is United Therapeutics Still a Hidden Gem After 34.9% Share Price Surge in 2025? - simplywall.st
Vinva Investment Management Ltd Raises Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
What is the fair value of United Therapeutics Corporation stock nowEarnings Overview Report & High Yield Equity Trading Tips - moha.gov.vn
Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells 11,000 Shares of Stock - MarketBeat
United Therapeutics Corporation $UTHR Shares Bought by Legal & General Group Plc - MarketBeat
United Therapeutics Executives Sell Shares Worth Over $15 Million - TradingView
[Form 4] UNITED THERAPEUTICS Corp Insider Trading Activity - Stock Titan
Journey Strategic Wealth LLC Takes Position in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (NASDAQ:UTHR) Stock Unloaded Rep. Lisa C. McClain - MarketBeat
Chmn Rothblatt Sells 8,000 ($3.8M) Of United Therapeutics Corp [UTHR] - TradingView
United Therapeutics stock hits all-time high at 485.43 USD - Investing.com
Vanguard Group Inc. Sells 8,287 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Prudential PLC Raises Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Has $12.56 Million Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corporation (UTHR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Heatmap analysis for United Therapeutics Corporation and competitorsJuly 2025 Highlights & Weekly Breakout Opportunity Watchlist - newser.com
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock - Yahoo Finance
Why United Therapeutics Corporation stock is trending among retail tradersMarket Trend Review & Precise Buy Zone Tips - newser.com
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
United Therapeutics Corp Stock (UTHR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Dec 11 '25 |
Option Exercise |
146.03 |
11,000 |
1,606,330 |
47,781 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Dec 11 '25 |
Sale |
484.67 |
11,000 |
5,331,316 |
36,781 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Dec 11 '25 |
Option Exercise |
120.26 |
4,000 |
481,040 |
4,130 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Dec 12 '25 |
Option Exercise |
120.26 |
4,000 |
481,040 |
4,130 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Dec 12 '25 |
Sale |
490.70 |
4,000 |
1,962,783 |
130 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Dec 11 '25 |
Sale |
483.97 |
4,000 |
1,935,879 |
130 |
1.26%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):